A vitamin D–based drug may offer a promising new approach in the treatment of pancreatic cancer by helping modify the tumor’s surrounding environment and potentially improving response to chemotherapy, according to early clinical research.
The findings come from a small clinical trial led by the Dana-Farber Cancer Institute, where researchers tested paricalcitol — an FDA-approved vitamin D analog already used for certain kidney-related conditions — in combination with standard chemotherapy for patients with metastatic pancreatic cancer.
The study included 36 patients who received gemcitabine and nab-paclitaxel alongside either a placebo or paricalcitol (given intravenously or orally). Researchers focused primarily on safety, and the combination was generally well tolerated, although some patients experienced manageable side effects such as elevated calcium levels.
Scientists observed that patients whose tumors had higher vitamin D receptor activity appeared to respond better to the treatment combination, showing improved chemotherapy response and longer survival outcomes compared to others in the study.
Pancreatic tumors are known for being difficult to treat because they develop a dense surrounding tissue that can block drugs and limit immune system access. In this study, paricalcitol appeared to reduce the activity of certain supportive cells within the tumor environment and allowed greater immune cell infiltration, which may help improve treatment effectiveness.
While the results are encouraging, researchers stress that the trial was small and not designed to confirm survival benefits. Larger clinical trials are needed to determine whether vitamin D–based therapies can significantly improve outcomes in pancreatic cancer patients.
Experts say the study highlights a potential new direction in cancer research, focusing on repurposing existing approved drugs to support conventional chemotherapy and overcome treatment resistance.
